AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14732641
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and written communication about the risks of the procedure (pamphlet)
Trial: 14732641
Drug: Oral communication
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral communication about the risks of the procedure (no pamphlet)
Trial: 14732641
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and written communication (pamphlet)
Trial: 31381494
Drug: Water-soluble chicken
RxNorm normalized name: Chicken
DrugBank: Chicken (DB10519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water-soluble chicken eggshell membrane (WSEM) 450 mg daily
Trial: 23035749
Drug: six 4‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: six 4‐mg doses of betamethasone every 8 h
Trial: 23035749
Drug: two 12‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two 12‐mg doses of betamethasone separated by 24 h
Trial: 12002834
Drug: occlusal splints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: occlusal splints and supplementary medical therapy (group II)
Trial: 12002834
Drug: occlusal splints
FDA approved: no
EMA approved: no
PMDA approved: no
Description: occlusal splints and physical therapy (group III)
Trial: 12002834
Drug: occlusal splints,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: occlusal splints, medical, and physical therapy (group IV)
Trial: 2223143
Drug: Oral melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral melphalan (0.25 mg/kg/day) with oral prednisone (2 mg/kg/day)
Trial: 2223143
Drug: Intravenous melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous melphalan (0.125 mg/kg/day) with oral prednisone (2 mg/kg/day)
Trial: 333855
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 mg - 40 mg)
Trial: 28538781
Drug: Passive cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive cycling exercise combined with conventional physical therapy (5 days per week)
Trial: 28538781
Drug: Passive cycling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive cycling exercise combined with conventional physical therapy
Trial: 20925442
Drug: Vardenafil ODT
RxNorm normalized name: Vardenafil Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil ODT (10 mg)
Trial: 20925442
Drug: Vardenafil FCT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil FCT (film-coated tablet)
Trial: 11554127
Drug: Azathioprine 100
RxNorm normalized name: azathioprine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 100 mg/day for 6 weeks
Trial: 9630326
Drug: CsA at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA at a dosage of 1 mg/kg/die (CsA1)
Trial: 9630326
Drug: CsA at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CsA at a dosage of 3 mg/kg/die (CsA3)
Trial: 3050268
Drug: High NaCl
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High NaCl diet (20 g/day)
Trial: 3050268
Drug: Low NaCl
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low NaCl diet (2 g/day)
Trial: 29354989
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication (Pinaverium bromide tablet, 50 mg, 3 times a day)
Trial: 25230980
Drug: Polypill (hydrochlorothiazide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polypill (hydrochlorothiazide, aspirin, atorvastatin, and either enalapril or valsartan)
Trial: 18811828
Drug: 6% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6% hydroxyethyl starch solution 130/0.42 (HES)
Trial: 18811828
Drug: 4% modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% modified fluid gelatin (GEL)
Trial: 16543549
Drug: Medical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical therapy arm of the National Emphysema Treatment Trial
Trial: 9384477
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with carmustine (300 mg/m2 x 1), etoposide (150 mg/m2 twice a day x 4 days), cytarabine (100 mg/m2 twice a day x 4 days), and cyclophosphamide (35 mg/kg x 4 days) followed by infusion of unmanipulated PBSC.
Trial: 9384477
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients who had failed primary induction chemotherapy (28 patients).
Trial: 9384477
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients in untreated first relapse (27 patients).
Trial: 9384477
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy (HDC) with PBSC infusion for patients who had reinduction attempts prior to receiving mobilization chemotherapy (18 patients).
Trial: 1585757
Drug: Micanol (new
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micanol (new dithranol formulation)
Trial: 30575682
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (>12 g/day) with NTG
Trial: 30575682
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (>12 g/day) without NTG
Trial: 30575682
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (<3 g/day) with NTG
Trial: 30575682
Drug: Low-salt diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-salt diet (<3 g/day) without NTG
Trial: 30575682
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (>12 g/day) with large body weight change
Trial: 30575682
Drug: High-salt diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-salt diet (>12 g/day) with small body weight change
Trial: 24825768
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy in Group 1 (37 patients)
Trial: 24825768
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy in Group 2 (18 patients)
Trial: 20664537
Drug: Oltipraz (30-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz (30-90 mg single dose; 60 mg b.i.d. or 90 mg q.d. for 24 weeks)
Trial: 15639067
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 800 mug
Trial: 15639067
Drug: Buccal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal misoprostol 800 mug
Trial: 8435265
Drug: Propofol 3
RxNorm normalized name: fospropofol 35 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 3 mg kg-1
Trial: 8435265
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg kg-1
Trial: 2448425
Drug: 10% hydroxyethylstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% hydroxyethylstarch (HES), 500 ml daily for 7 days
Trial: 2448425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without HES infusion
Trial: 29924703
Drug: Protein-enhanced diet
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein-enhanced diet (1.2 g protein/kg body weight/day with 30 g protein/meal), n=41
Trial: 29924703
Drug: Control diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control diet (0.8 g protein/kg body weight/day), n=21
Trial: 26850888
Drug: Optimized group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized group 1 (individualized treatment in 30 DM cases)
Trial: 29335895
Drug: Rilpivirine 25
RxNorm normalized name: rilpivirine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilpivirine 25 mg once daily
Trial: 16564942
Drug: Intravenous vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous vitamin C (300 mg with each dialysis session)
Trial: 16492717
Drug: Fontolizumab 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab 0.1 mg/kg
Trial: 16492717
Drug: Fontolizumab 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab 1.0 mg/kg
Trial: 16492717
Drug: Fontolizumab 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab 4.0 mg/kg
Trial: 16492717
Drug: Fontolizumab (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fontolizumab (all doses)
Trial: 10840987
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (500 ml/day)
Trial: 23879615
Drug: Immediate functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate functional loading implants (test group 1) with conventional drilling procedure
Trial: 23879615
Drug: Immediate functional
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate functional loading implants (test group 2) with modified implant installation procedure (osteotome technique)
Trial: 23879615
Drug: Conventional drilling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drilling procedure with submerged implants for 3 months (control group)
Trial: 23879615
Drug: All implants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implants (combined data)
Trial: 21951832
Drug: sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sitagliptin 100 mg qd
Trial: 18165450
Drug: Long chain
RxNorm normalized name: long chain triglycerides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long chain triglycerides (LCT) infusion for 5 days postoperatively
Trial: 18165450
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no LCT infusion)
Trial: 17198491
Drug: Experimental nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental nutritional formula (EXP) 240 mL/d for 4 weeks before and 6 weeks after influenza vaccination
Trial: 10928427
Drug: i.m. progesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.m. progesterone formulation, 50 mg
Trial: 8628712
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 7 gms/L of fiber
Trial: 8628712
Drug: Formula containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula containing 14 gms/L of fiber
Trial: 3893732
Drug: MDL 72,222
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDL 72,222 (20-40 mg)
Trial: 29885997
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT, followed by 3 cycles of cisplatin (80 mg/m2) and fluorouracil (1000 mg/m2/day for 4 days)
Trial: 29885997
Drug: Chemoradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation therapy (CRT) with 3 cycles of cisplatin (100 mg/m2) concurrent with RT
Trial: 27668585
Drug: CT-guided lumbosacral
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided lumbosacral facet joint injection of methylprednisolone acetate (0.1 mg/kg)
Trial: 27668585
Drug: CT-guided transforaminal
RxNorm normalized name: transforming growth factor beta 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided transforaminal epidural injection of methylprednisolone acetate (0.1 mg/kg)
Trial: 27668585
Drug: CT-guided translaminar
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided translaminar epidural injection of methylprednisolone acetate (0.1 mg/kg)
Trial: 24019126
Drug: Famotidine 40
RxNorm normalized name: famotidine 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 40 mg orally, twice daily, 4 and 3 hours before each radiotherapy fraction
Trial: 20305869
Drug: 25% citric
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% citric acid solution
Trial: 20305869
Drug: 24% EDTA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% EDTA gel
Trial: 20305869
Drug: tetracycline solution
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tetracycline solution (50 mg/mL)
Trial: 20305869
Drug: 30% sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% sodium citrate solution
Trial: 20305869
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: saline solution irrigation
Trial: 15549690
Drug: Hypericum perforatum
RxNorm normalized name: Hypericum perforatum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypericum perforatum (St. John's Wort), duration of treatment not specified.
Trial: 15549690
Drug: Not applicable,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable, as the study mentions that beliefs did not mediate the effect of treatment on depression.
Trial: 8516819
Drug: Monoclonal IL‐2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal IL‐2 receptor antibody therapy as part of a quadruple immunosuppressive regimen
Trial: 8516819
Drug: ATG as
RxNorm normalized name: equine ATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG as induction therapy
Trial: 31096036
Drug: Umeclidinium/vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg
Trial: 24830577
Drug: OSS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSS plus SF‐ELS (split dose)
Trial: 24830577
Drug: OSS plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSS plus SF‐ELS (entire dose)
Trial: 24830577
Drug: PEG‐EA (split
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐EA (split dose)
Trial: 24830577
Drug: Bisacodyl plus
RxNorm normalized name: Bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bisacodyl plus SF‐ELS (same-day preparation)
Trial: 19407953
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine combined with acitretin capsule
Trial: 19407953
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine alone
Trial: 19407953
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (Chinese herbal medicine with and without acitretin)
Trial: 17574073
Drug: Histologic type
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histologic type (S, CC, E)
Trial: 17574073
Drug: Histology (S,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histology (S, CC)
Trial: 16264181
Drug: 5 years
RxNorm normalized name: Dymadon 5 Years Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 years of adjuvant tamoxifen therapy
Trial: 16264181
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of adjuvant tamoxifen therapy
Trial: 10901847
Drug: Antiretroviral (ARV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral (ARV) drugs (zidovudine with or without lamivudine or nevirapine)
Trial: 10901847
Drug: Confidential, voluntary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Confidential, voluntary HIV screening and counseling of pregnant women with short-course ARV treatment during the perinatal period
Trial: 10901847
Drug: Post-exposure prophylaxis
RxNorm normalized name: Anthrax, post-exposure prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-exposure prophylaxis using ARV drugs in newborns
Trial: 8848900
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) administered continuously during 60 min
Trial: 1691806
Drug: Aprotinin infusion
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin infusion (total 6.10(6) KIU) before and during bypass
Trial: 451497
Drug: 10% glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% glycerol solution
Trial: 451497
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose solution (placebo)
Trial: 31083231
Drug: 3.7 MBq
RxNorm normalized name: Sodium iodide (123-I) 3.7 MBq oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.7 MBq I‐131/g thyroid plus 600 mg/day LiCO3
Trial: 31083231
Drug: 5.55 MBq
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5.55 MBq I‐131/g plus 600 mg/day LiCO3
Trial: 31083231
Drug: 7.4 MBq
RxNorm normalized name: Sodium iodide (123-I) 7.4 MBq oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.4 MBq I‐131/g without LiCO3
Trial: 31083231
Drug: 7.4 MBq
RxNorm normalized name: Sodium iodide (123-I) 7.4 MBq oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.4 MBq I‐131/g
Trial: 25582309
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of iron (Fe) plus 30 mg of zinc (Zn) for 3 months
Trial: 25582309
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of zinc (Zn) plus 30 mg of iron (Fe) for 3 months
Trial: 23580239
Drug: sorafenib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib 600 mg twice daily
Trial: 19211442
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg of aspirin
Trial: 16895892
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake of 1140 mg/d
Trial: 16895892
Drug: Calcium intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium intake range (700-2100 mg/d)
Trial: 15098883
Drug: Leuprorelin, 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin, 0.5 mg/d subcutaneously (group A)
Trial: 15098883
Drug: Leuprorelin, 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin, 3.75 mg depot (group B)
Trial: 8036680
Drug: Primaquine 15
RxNorm normalized name: primaquine 15 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 15 mg for 14 days
Trial: 8036680
Drug: Primaquine 22.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primaquine 22.5 mg for 14 days
Trial: 8036680
Drug: Chloroquine 300
RxNorm normalized name: chloroquine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine 300 mg on the first day
Trial: 8036680
Drug: Chloroquine 450
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine 450 mg on the first day
Trial: 2675651
Drug: Ibuprofen 600
RxNorm normalized name: ibuprofen 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 600 mg tablets taken four times a day for 4 to 6 days
Trial: 1266277
Drug: Imipramine 25
RxNorm normalized name: trimipramine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 25 mg (22.1 mg free base)
Trial: 1266277
Drug: Dimetacrine 33.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimetacrine 33.5 mg (21.4 mg free base)
Trial: 1266277
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants during ergometric exercise
Trial: 31945895
Drug: STAR-IO (insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STAR-IO (insulin only version)
Trial: 28189364
Drug: SC401 (1530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC401 (1530 mg EPA‐ethyl esters and DHA‐EEs)
Trial: 28189364
Drug: Lovaza (3600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovaza (3600 mg ω‐3)
Trial: 22277329
Drug: HPV16/18 antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV16/18 antibody or DNA testing
Trial: 10332441
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily controlled release oxybutynin
Trial: 8622042
Drug: CSF (granulocyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSF (granulocyte [G]- or granulocyte-macrophage [GM]-CSF)
Trial: 8622042
Drug: Vincristine (cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine (cumulative dose in the first cycle)
Trial: 1777913
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg 3 times daily)
Trial: 6811379
Drug: Levonorgestrel 250
RxNorm normalized name: ethinyl estradiol 30 MCG / levonorgestrel 250 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levonorgestrel 250 μg combined with 30 μg ethinyl estradiol